Home>>Signaling Pathways>> GPCR/G protein>> Neurotensin Receptors>>AF38469

AF38469

Catalog No.GC19023

AF38469 is a novel, selective, orally bioavailable Sortilin inhibitor with an IC50 value of 330 nM.

Products are for research use only. Not for human use. We do not sell to patients.

AF38469 Chemical Structure

Cas No.: 1531634-31-7

Size Price Stock Qty
10mM (in 1mL DMSO)
$205.00
In stock
2mg
$124.00
In stock
5mg
$186.00
In stock
10mg
$297.00
In stock
25mg
$585.00
In stock
50mg
$936.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Chemical Properties Product Documents Related Products

AF38469 is a novel, selective, orally bioavailable Sortilin inhibitor with an IC50 value of 330 nM.

AF38469 showed no inhibition or stimulation of >50% at 10 uM in a standard selectivity panel of ca. 70 targets run at CEREP. Importantly AF38469 showed no activity against the NTR1 receptor. In addition AF38469 showed no activity against a selected panel of targets known to bind acidic molecules (d-Opioid, GPR40, PPARd, EP1, Angiotensin AT1, Endothelin ETA & B, MMP-12). AF38469 will serve as an important tool to further delineate the biology of Sortilin, and to facilitate evaluation of the therapeutic potential of this protein[1].

References:
[1]. Schroder TJ, et al. The identification of AF38469: an orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin. Bioorg Med Chem Lett. 2014 Jan 1;24(1):177-80.

Reviews

Review for AF38469

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AF38469

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.